A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

Sira Nanthapisal, Thanyawee Puthanakit, Peera Jaru-Ampornpan, Rapisa Nantanee, Pimpayao Sodsai, Orawan Himananto, Jiratchaya Sophonphan, Pintip Suchartlikitwong, Narin Hiransuthikul, Pornpimon Angkasekwinai, Auchara Tangsathapornpong, Nattiya Hirankarn the study team
doi: https://doi.org/10.1101/2022.02.15.22270974

Article Information

doi 
https://doi.org/10.1101/2022.02.15.22270974
History 
  • February 15, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Sira Nanthapisal, MD, PhDa,l,m,
  2. Thanyawee Puthanakit, MDb,†,
  3. Peera Jaru-Ampornpan, PhDc,
  4. Rapisa Nantanee, MDb,d,
  5. Pimpayao Sodsai, PhDe,
  6. Orawan Himanantof,
  7. Jiratchaya Sophonphan, MScg,
  8. Pintip Suchartlikitwong, MDh,
  9. Narin Hiransuthikul, MD, PhDi,
  10. Pornpimon Angkasekwinai, PhDj,k,l,
  11. Auchara Tangsathapornpong, MDa,l,*,
  12. Nattiya Hirankarn, MD, PhDe,* and
  13. the study team**
  1. aDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
  2. bCenter of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  3. cVirology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)
  4. dPediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  5. eCenter of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  6. fMonoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC)
  7. gThe HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
  8. hDepartment of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  9. iDepartment of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  10. jDepartment of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumthani, Thailand
  11. kResearch Unit in Molecular Pathogenesis and Immunology of Infectious Diseases, Thammasat University, Pathumthani, Thailand
  12. lResearch Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
  13. mClinical Research Center, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
  1. ↵†Corresponding author:
    Thanyawee Puthanakit, MD, Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV, Pathumwan, Bangkok, 10330, Thailand. Telephone: +662 2564930, E-mail: thanyawee.p{at}chula.ac.th

  1. ↵* Contributed equally

Back to top
Posted February 15, 2022.
Download PDF
Data/Code
Email
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
Sira Nanthapisal, Thanyawee Puthanakit, Peera Jaru-Ampornpan, Rapisa Nantanee, Pimpayao Sodsai, Orawan Himananto, Jiratchaya Sophonphan, Pintip Suchartlikitwong, Narin Hiransuthikul, Pornpimon Angkasekwinai, Auchara Tangsathapornpong, Nattiya Hirankarn
medRxiv 2022.02.15.22270974; doi: https://doi.org/10.1101/2022.02.15.22270974
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area